STANDARD LITHIUM LTD. SLI

Healthcare SIC 2800 - Chemicals & Allied Products NAICS Manufacturing › Chemical Manufacturing derived NYSE

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021
Operating income -$27.4M-$33.5M———
Net income -$48.4M$105.8M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021
Total assets $386.5M$287.3M$130.9M——
Total equity $354.0M$248.4M$120.2M——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-130448.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -50M 0 50M 100M 150M Net income, FY2024: 105.8M Net income, FY2025: -48.4M FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2021FY2022FY2023FY2024FY2025
Revenue — — — — —
Gross profit — — — — —
Net income — — — $105.8M -$48.4M

Others in SIC 2800

TickerCompanyMarket capP/ERevenue growth
SOLS Solstice Advanced Materials Inc. $9.44B 39.9x 3.1%
BCPC BALCHEM CORP $5.64B 37.3x 8.8%
PRM Perimeter Solutions, Inc. $4.55B — 16.4%
IOSP INNOSPEC INC. $2.43B 21.1x -3.7%
NGVT Ingevity Corp $2.39B — -2.7%
CC Chemours Co $1.93B — 0.4%
OLN OLIN Corp $1.78B — 3.7%
HUN Huntsman CORP $1.54B — -5.8%